X4 Pharmaceuticals, Inc
XFORDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 14, 2026
6wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How XFOR's past catalysts played out
Mavorixafor
WHIM Syndrome
X4P-001
WHIM Syndrome
axitinib
Clear Cell Renal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mavorixafor | Phase 3 | WHIM Syndrome | - | - |
X4P-001 | Phase 2 | WHIM Syndrome | - | - |
axitinib | Phase 2 | Clear Cell Renal Cell Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in X4 Pharmaceuticals, Inc's drug pipeline?→
CatalystAlert tracks 3 drug candidates in X4 Pharmaceuticals, Inc's (XFOR) pipeline across Phase 3, Phase 2. Its lead program is Mavorixafor (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is X4 Pharmaceuticals, Inc's next FDA catalyst?→
X4 Pharmaceuticals, Inc's (XFOR) next tracked catalyst is a Earnings expected August 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track XFOR biotech catalysts?→
Add XFOR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow X4 Pharmaceuticals, Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.